96% of gross portfolio value is concentrated in later stage companies within our core portfolio.

COMPANYTHERAPEUTIC AREADISCOVERYPRECLINICALPHASE 1PHASE 2PHASE 3

Core portfolio

IterumAnti-infectives
AtoxImmunology & inflammation
AuraOncology
VeronaImmunology & inflammation
AmplyxAnti-infectives
PharmaxisImmunology & inflammation
ImaraRare diseases
AutolusOncology
HarpoonOncology
VelosBioOncology
ArtiosOncology
LogicBioRare diseases

Discovery portfolio

Multiple*Multiple

* This includes Depixus, PreciThera, Mitoconix, OptiKira and a new company focused on inhibiting highly inflammatory processes in the innate immune system.

Core Portfolio (clinical)

Core Portfolio (pre-clinical)

Discovery Portfolio

Pipeline

Preclinical

25+

Phase 1

12

Phase 2

10

Phase 3

4

Expected catalysts in 2019

Phase 1

8

Data readouts

6

Initiations

Phase 2

7

Data readouts

1

Initiations

Phase 3

4

Data readouts

>1

Initiation